BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD. Complementing the Cancer-Immunity Cycle. Front Immunol 2019;10:774. [PMID: 31031765 DOI: 10.3389/fimmu.2019.00774] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 25.3] [Reference Citation Analysis]
Number Citing Articles
1 Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, Sadat Hosseini G, Gholami N, Janati S. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology 2022;113:109365. [DOI: 10.1016/j.intimp.2022.109365] [Reference Citation Analysis]
2 Kodintseva EА, Akleуev AA. Effect of chronic exposure on the concentration of NF-kB in peripheral blood lymphocytes. Ekologiya cheloveka (Human Ecology) 2022. [DOI: 10.17816/humeco108084] [Reference Citation Analysis]
3 Gu L, Pan X, Wang C, Wang L. The benefits of propofol on cancer treatment: Decipher its modulation code to immunocytes. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.919636] [Reference Citation Analysis]
4 Loacker L, Kimpel J, Bánki Z, Schmidt CQ, Griesmacher A, Anliker M. Increased PD-L1 surface expression on peripheral blood granulocytes and monocytes after vaccination with SARS-CoV2 mRNA or vector vaccine. Clin Chem Lab Med 2022. [PMID: 36245120 DOI: 10.1515/cclm-2022-0787] [Reference Citation Analysis]
5 Yang T, Xiong Y, Zeng Y, Wang Y, Zeng J, Liu J, Xu S, Li L. Current status of immunotherapy for non-small cell lung cancer. Front Pharmacol 2022;13:989461. [DOI: 10.3389/fphar.2022.989461] [Reference Citation Analysis]
6 Yuan M, Liu L, Wang C, Zhang Y, Zhang J. The Complement System: A Potential Therapeutic Target in Liver Cancer. Life (Basel) 2022;12:1532. [PMID: 36294966 DOI: 10.3390/life12101532] [Reference Citation Analysis]
7 Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol 2022;12:958720. [DOI: 10.3389/fonc.2022.958720] [Reference Citation Analysis]
8 Chun J, Kang HN, Yi J, Hong SH, Park S, Jeong M. Bojungikki-Tang Enhances the Effect of PD-1 Blockade in a Syngeneic Murine Model of Lung Carcinoma. Processes 2022;10:1683. [DOI: 10.3390/pr10091683] [Reference Citation Analysis]
9 Wen J, Zhao Y, Fang C, Wu X. Association between serum baseline C1q and IgG levels and the efficacy of combined immunotherapy in patients with esophageal squamous cell carcinoma: a retrospective study. Immunopharmacology and Immunotoxicology. [DOI: 10.1080/08923973.2022.2115926] [Reference Citation Analysis]
10 Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 2022. [PMID: 35974096 DOI: 10.1038/s41573-022-00520-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Phung CD, Nguyen BL, Jeong J, Chang J, Jin SG, Choi H, Ku SK, Kim JO. Shaping the “hot” immunogenic tumor microenvironment by nanoparticles co‐delivering oncolytic peptide and TGF ‐β1 siRNA for boosting checkpoint blockade therapy. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Magrini E, Minute L, Dambra M, Garlanda C. Complement activation in cancer: Effects on tumor-associated myeloid cells and immunosuppression. Semin Immunol 2022;:101642. [PMID: 35842274 DOI: 10.1016/j.smim.2022.101642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang W, Li L, Wu S, Shen J, Huang C, Chen Y, Li S. Abscopal effect of radiation therapy and nivolumab in a patient with combined small-cell lung cancer: a case report. Immunotherapy 2022. [PMID: 35787148 DOI: 10.2217/imt-2021-0050] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tampe D, Kopp SB, Baier E, Hakroush S, Tampe B. Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity. Front Med (Lausanne) 2022;9:902256. [PMID: 35755033 DOI: 10.3389/fmed.2022.902256] [Reference Citation Analysis]
15 Hou Y, Zhang R, Zong J, Wang W, Zhou M, Yan Z, Li T, Gan W, Lv S, Zeng Z, Yang M. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer. Front Immunol 2022;13:892512. [PMID: 35711437 DOI: 10.3389/fimmu.2022.892512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Koustas E, Trifylli EM, Sarantis P, Papadopoulos N, Karapedi E, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives. Int J Mol Sci 2022;23:6664. [PMID: 35743107 DOI: 10.3390/ijms23126664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Stakhovskyi O, Kobyliak N, Voylenko O, Stakhovskyi E, Ponomarchuk R, Sulaieva O. Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis. Cells 2022;11:1802. [DOI: 10.3390/cells11111802] [Reference Citation Analysis]
18 Bahri R, Kiss O, Prise I, Garcia-rodriguez KM, Atmoko H, Martínez-gómez JM, Levesque MP, Dummer R, Smith MP, Wellbrock C, Bulfone-paus S. Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor Prognosis. Front Immunol 2022;13:861545. [DOI: 10.3389/fimmu.2022.861545] [Reference Citation Analysis]
19 Lu C, Miao J, Li M, Zheng Q, Xu F, Pan Y, Wang Y, Yang Z, Xia X, Zhu H, Chen J, Bao S. Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. Front Oncol 2022;12:870840. [DOI: 10.3389/fonc.2022.870840] [Reference Citation Analysis]
20 Alausa A, Victor UC, Fadahunsi OS, Owolabi N, Adeniji A, Olatinwo M, Ogunlana AT, Olaleke B, Balogun TA, Ogundepo S, Adegboola PI. Checkpoints and Immunity in Cancers: Role of GNG12. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106242] [Reference Citation Analysis]
21 Dai J, Dong X, Liu R, Chen B, Dong X, Wang Q, Hu J, Xia F, Lou X. A peptide-AIEgen nanocomposite mediated whole cancer immunity cycle-cascade amplification for improved immunotherapy of tumor. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
22 Mirian M, Hariri A, Yadollahi M, Kohandel M. Circadian and Immunity Cycle Talk in Cancer Destination: From Biological Aspects to In Silico Analysis. Cancers 2022;14:1578. [DOI: 10.3390/cancers14061578] [Reference Citation Analysis]
23 Poggi A, Zocchi MR. Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. Mol Ther Oncolytics 2022;24:26-42. [PMID: 34977340 DOI: 10.1016/j.omto.2021.11.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
24 Anliker M, Drees D, Loacker L, Hafner S, Griesmacher A, Hoermann G, Fux V, Schennach H, Hörtnagl P, Dopler A, Schmidt S, Bellmann-Weiler R, Weiss G, Marx-Hofmann A, Körper S, Höchsmann B, Schrezenmeier H, Schmidt CQ. Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation. J Immunol 2022;208:1248-58. [PMID: 35173033 DOI: 10.4049/jimmunol.2100031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Figueroa I, Gupta A, Peighambari A. T-Cell Based Therapies: Clinical Applications and Challenges. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_185-1] [Reference Citation Analysis]
26 Li X, Sun H, Liu Q, Liu Y, Hou Y, Jin W. Conjoint analysis of circulating tumor cells and solid tumors for exploring potential prognostic markers and constructing a robust novel predictive signature for breast cancer. Cancer Cell Int 2021;21:708. [PMID: 34953500 DOI: 10.1186/s12935-021-02415-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Von Rueden SK, Fan TM. Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. Front Oncol 2021;11:773420. [PMID: 34869014 DOI: 10.3389/fonc.2021.773420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Huang YK, Busuttil RA, Boussioutas A. The Role of Innate Immune Cells in Tumor Invasion and Metastasis. Cancers (Basel) 2021;13:5885. [PMID: 34884995 DOI: 10.3390/cancers13235885] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y, Li N, Zhou P, Chu Q, Wu K. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol 2021;14:146. [PMID: 34526097 DOI: 10.1186/s13045-021-01155-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
30 Senent Y, Ajona D, González-Martín A, Pio R, Tavira B. The Complement System in Ovarian Cancer: An Underexplored Old Path. Cancers (Basel) 2021;13:3806. [PMID: 34359708 DOI: 10.3390/cancers13153806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jiang F, Mao Y, Lu B, Zhou G, Wang J. A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia. Sci Rep 2021;11:14657. [PMID: 34282207 DOI: 10.1038/s41598-021-94128-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
32 Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update. Biomedicines 2021;9:835. [PMID: 34356899 DOI: 10.3390/biomedicines9070835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
33 He L, Zhang Q, Zhang Y, Fan Y, Yuan F, Li S. Single-cell analysis reveals cell communication triggered by macrophages associated with the reduction and exhaustion of CD8+ T cells in COVID-19. Cell Commun Signal 2021;19:73. [PMID: 34238338 DOI: 10.1186/s12964-021-00754-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
34 Grunenwald A, Roumenina LT. The Benefits of Complement Measurements for the Clinical Practice. Methods Mol Biol 2021;2227:1-20. [PMID: 33847926 DOI: 10.1007/978-1-0716-1016-9_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Pham LM, Poudel K, Ou W, Phung CD, Nguyen HT, Nguyen BL, Karmacharya P, Pandit M, Chang JH, Jeong JH, Ku SK, Yong CS, Choi HG, Kim JO. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles. Int J Pharm 2021;605:120816. [PMID: 34161810 DOI: 10.1016/j.ijpharm.2021.120816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
36 Wang L, He T, Liu J, Tai J, Wang B, Chen Z, Quan Z. Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment. Exp Hematol Oncol 2021;10:31. [PMID: 33971970 DOI: 10.1186/s40164-021-00226-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
37 Choong WK, Sung TY. Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities. iScience 2021;24:102522. [PMID: 34142036 DOI: 10.1016/j.isci.2021.102522] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Lu P, Ma Y, Wei S, Liang X. The dual role of complement in cancers, from destroying tumors to promoting tumor development. Cytokine 2021;143:155522. [PMID: 33849765 DOI: 10.1016/j.cyto.2021.155522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Zhu H, Yu X, Zhang S, Shu K. Targeting the Complement Pathway in Malignant Glioma Microenvironments. Front Cell Dev Biol 2021;9:657472. [PMID: 33869223 DOI: 10.3389/fcell.2021.657472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
40 Amere Subbarao S. Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. Inflammopharmacology 2021;29:343-66. [PMID: 33723711 DOI: 10.1007/s10787-021-00796-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
41 Curran CS, Kopp JB. PD-1 immunobiology in glomerulonephritis and renal cell carcinoma. BMC Nephrol 2021;22:80. [PMID: 33676416 DOI: 10.1186/s12882-021-02257-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
42 Angeles CV, Sabel MS. Immunotherapy for Merkel cell carcinoma. J Surg Oncol 2021;123:775-81. [PMID: 33595894 DOI: 10.1002/jso.26319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
43 Marwitz S, Ballesteros-Merino C, Jensen SM, Reck M, Kugler C, Perner S, Drömann D, Goldmann T, Fox BA. Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer. J Immunother Cancer 2021;9:e001469. [PMID: 33589523 DOI: 10.1136/jitc-2020-001469] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
44 Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen L, Zhou J. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Ther Adv Med Oncol 2021;13:1758835921992968. [PMID: 33643442 DOI: 10.1177/1758835921992968] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 15.0] [Reference Citation Analysis]
45 Yang H, Li L, Liu X, Zhao Y. High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels. Med Sci Monit 2021;27:e927977. [PMID: 33539329 DOI: 10.12659/MSM.927977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 武 淑. Research Progress of the Effect of Multimodal Analgesia on the Perioperative Immune Functions and Long-Term Survival for Patients with Lung Cancer. ACM 2021;11:1518-1525. [DOI: 10.12677/acm.2021.114217] [Reference Citation Analysis]
47 Takeshita T, Torigoe T, Yan L, Huang JL, Yamashita H, Takabe K. The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer. Cancers (Basel) 2020;13:E110. [PMID: 33396390 DOI: 10.3390/cancers13010110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
48 Koulouridi A, Messaritakis I, Gouvas N, Tsiaoussis J, Souglakos J. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer. Cancers (Basel) 2020;13:E43. [PMID: 33375686 DOI: 10.3390/cancers13010043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
49 Herbert A. Complement controls the immune synapse and tumors control complement. J Immunother Cancer 2020;8:e001712. [PMID: 33323465 DOI: 10.1136/jitc-2020-001712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Qiu H, Li Y, Cheng S, Li J, He C, Li J. A Prognostic Microenvironment-Related Immune Signature via ESTIMATE (PROMISE Model) Predicts Overall Survival of Patients With Glioma. Front Oncol 2020;10:580263. [PMID: 33425732 DOI: 10.3389/fonc.2020.580263] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
52 Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res 2021;149:103-42. [PMID: 33579422 DOI: 10.1016/bs.acr.2020.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
53 Ma R, Yi B, Riker AI, Xi Y. Metformin and cancer immunity. Acta Pharmacol Sin 2020;41:1403-9. [PMID: 32868904 DOI: 10.1038/s41401-020-00508-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
54 Korbecki J, Olbromski M, Dzięgiel P. CCL18 in the Progression of Cancer. Int J Mol Sci 2020;21:E7955. [PMID: 33114763 DOI: 10.3390/ijms21217955] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
55 Xiong D, Wang Y, You M. A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response. Nat Commun 2020;11:5084. [PMID: 33033253 DOI: 10.1038/s41467-020-18546-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
56 Roder J, Net L, Oliveira C, Meyer K, Asmellash S, Kasimir-Bauer S, Pass H, Weber J, Roder H, Grigorieva J. A proposal for score assignment to characterize biological processes from mass spectral analysis of serum. Clin Mass Spectrom 2020;18:13-26. [PMID: 34820522 DOI: 10.1016/j.clinms.2020.09.001] [Reference Citation Analysis]
57 Ding P, Li L, Li L, Lv X, Zhou D, Wang Q, Chen J, Yang C, Xu E, Dai W, Zhang X, Wang N, Wang Q, Zhang W, Zhang L, Zhou Y, Gu H, Lei Q, Zhou X, Hu W. C5aR1 is a master regulator in Colorectal Tumorigenesis via Immune modulation. Theranostics 2020;10:8619-32. [PMID: 32754267 DOI: 10.7150/thno.45058] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
58 Chen X, Jin Y, Gong L, He D, Cheng Y, Xiao M, Zhu Y, Wang Z, Cao K. Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer. Front Genet 2020;11:607. [PMID: 32655621 DOI: 10.3389/fgene.2020.00607] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
59 Chow SH, Deo P, Yeung ATY, Kostoulias XP, Jeon Y, Gao ML, Seidi A, Olivier FAB, Sridhar S, Nethercott C, Cameron D, Robertson AAB, Robert R, Mackay CR, Traven A, Jin ZB, Hale C, Dougan G, Peleg AY, Naderer T. Targeting NLRP3 and Staphylococcal pore-forming toxin receptors in human-induced pluripotent stem cell-derived macrophages. J Leukoc Biol 2020;108:967-81. [PMID: 32531864 DOI: 10.1002/JLB.4MA0420-497R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
60 Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Bayani J, Bartlett J, Xu B, Downes MR. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study. J Clin Pathol 2021;74:53-7. [PMID: 32471889 DOI: 10.1136/jclinpath-2020-206631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Golay J, Andrea AE. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies (Basel) 2020;9:E17. [PMID: 32443877 DOI: 10.3390/antib9020017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
62 Netti GS, Lucarelli G, Spadaccino F, Castellano G, Gigante M, Divella C, Rocchetti MT, Rascio F, Mancini V, Stallone G, Carrieri G, Gesualdo L, Battaglia M, Ranieri E. PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging (Albany NY) 2020;12:7585-602. [PMID: 32345771 DOI: 10.18632/aging.103169] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 16.0] [Reference Citation Analysis]
63 Koustas E, Sarantis P, Papavassiliou AG, Karamouzis MV. The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. Biomolecules 2020;10:E666. [PMID: 32344837 DOI: 10.3390/biom10050666] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
64 Sinha A, Singh V, Tandon R, Mohan Srivastava L. Dichotomy of complement system: Tumorigenesis or destruction. Immunol Lett 2020;223:89-96. [PMID: 32333965 DOI: 10.1016/j.imlet.2020.04.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
65 Teijeira Á, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, de Andrea C, Ochoa MC, Otano I, Etxeberria I, Andueza MP, Nieto CP, Resano L, Azpilikueta A, Allegretti M, de Pizzol M, Ponz-Sarvisé M, Rouzaut A, Sanmamed MF, Schalper K, Carleton M, Mellado M, Rodriguez-Ruiz ME, Berraondo P, Perez-Gracia JL, Melero I. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity 2020;52:856-871.e8. [PMID: 32289253 DOI: 10.1016/j.immuni.2020.03.001] [Cited by in Crossref: 198] [Cited by in F6Publishing: 161] [Article Influence: 99.0] [Reference Citation Analysis]
66 Zhang X, Quan F, Xu J, Xiao Y, Li X, Li Y. Combination of multiple tumor-infiltrating immune cells predicts clinical outcome in colon cancer. Clin Immunol 2020;215:108412. [PMID: 32278085 DOI: 10.1016/j.clim.2020.108412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
67 Pourmollaei S, Barzegari A, Farshbaf-Khalili A, Nouri M, Fattahi A, Shahnazi M, Dittrich R. Anticancer effect of bacteria on cervical cancer: Molecular aspects and therapeutic implications. Life Sci 2020;246:117413. [PMID: 32035929 DOI: 10.1016/j.lfs.2020.117413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
68 Kumar D, Romero Y, Schuck KN, Smalley H, Subedi B, Fleming SD. Drivers and regulators of humoral innate immune responses to infection and cancer. Mol Immunol 2020;121:99-110. [PMID: 32199212 DOI: 10.1016/j.molimm.2020.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
69 Fattahi F, Zetoune FS, Ward PA. Complement as a Major Inducer of Harmful Events in Infectious Sepsis. Shock 2020;54:595-605. [PMID: 32187106 DOI: 10.1097/SHK.0000000000001531] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
70 Gordon S, Plüddemann A, Mukhopadhyay S. Plasma membrane receptors of tissue macrophages: functions and role in pathology. J Pathol 2020;250:656-66. [PMID: 32086805 DOI: 10.1002/path.5404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
71 Kumar A, Chamoto K, Chowdhury PS, Honjo T. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. Elife 2020;9:e52330. [PMID: 32122466 DOI: 10.7554/eLife.52330] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
72 Wen Q, Han T, Wang Z, Jiang S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Oncol Lett. 2020;19:2595-2601. [PMID: 32218809 DOI: 10.3892/ol.2020.11369] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
73 Grigorieva J, Asmellash S, Net L, Tsypin M, Roder H, Roder J. Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach. Int J Mol Sci 2020;21:E838. [PMID: 32012941 DOI: 10.3390/ijms21030838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
74 Afonso J, Santos LL, Longatto-Filho A, Baltazar F. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. Nat Rev Urol 2020;17:77-106. [PMID: 31953517 DOI: 10.1038/s41585-019-0263-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 27.0] [Reference Citation Analysis]
75 Karjalainen A, Shoebridge S, Krunic M, Simonović N, Tebb G, Macho-Maschler S, Strobl B, Müller M. TYK2 in Tumor Immunosurveillance. Cancers (Basel) 2020;12:E150. [PMID: 31936322 DOI: 10.3390/cancers12010150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
76 Grigorieva J, Asmellash S, Oliveira C, Roder H, Net L, Roder J. Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests. Clinical Mass Spectrometry 2020;15:44-53. [DOI: 10.1016/j.clinms.2019.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
77 Mohebnasab M, Eriksson O, Persson B, Sandholm K, Mohlin C, Huber-Lang M, Keating BJ, Ekdahl KN, Nilsson B. Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics. Front Immunol 2019;10:2539. [PMID: 31787968 DOI: 10.3389/fimmu.2019.02539] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
78 Cefalì M, Efstathopoulou A, De Dosso S, Saletti P. Lymphocyte count and lymphocyte-to-white blood cells ratio as indicators of survival in specific cancer subtypes. Int Immunopharmacol 2019;77:105982. [PMID: 31677993 DOI: 10.1016/j.intimp.2019.105982] [Reference Citation Analysis]
79 Roumenina LT, Daugan MV, Petitprez F, Sautès-Fridman C, Fridman WH. Context-dependent roles of complement in cancer. Nat Rev Cancer 2019;19:698-715. [PMID: 31666715 DOI: 10.1038/s41568-019-0210-0] [Cited by in Crossref: 127] [Cited by in F6Publishing: 136] [Article Influence: 42.3] [Reference Citation Analysis]
80 Kumar A, Chamoto K, Chowdhury PS, Honjo T. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.. [DOI: 10.1101/813584] [Reference Citation Analysis]
81 Wang X, Iyer A, Lyons AB, Körner H, Wei W. Emerging Roles for G-protein Coupled Receptors in Development and Activation of Macrophages. Front Immunol 2019;10:2031. [PMID: 31507616 DOI: 10.3389/fimmu.2019.02031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
82 Peng D, Wang L, Li H, Cai C, Tan Y, Xu B, Le H. An immune infiltration signature to predict the overall survival of patients with colon cancer. IUBMB Life 2019;71:1760-70. [PMID: 31301220 DOI: 10.1002/iub.2124] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
83 Martinek J, Wu T, Cadena D, Banchereau J, Palucka K. Interplay between dendritic cells and cancer cells. Immunobiology of Dendritic Cells Part A. Elsevier; 2019. pp. 179-215. [DOI: 10.1016/bs.ircmb.2019.07.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]